Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis

James W. Hainer, Donald J. Sherrard, Suzanne K. Swan, Jeffrey S. Barrett, Christopher A. Assaid, Michael J. Fossler, Donna S. Cox, Robert M. Williams, Amy L. Pittenger, Carol A. Stephenson, Tsushung A. Hua

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


Background: Patients with end-stage renal disease are subject to a broad range of thrombotic complications. Low molecular weight heparins (LMWHs) are effective antithrombotic agents; however, they are cleared largely by renal mechanisms, raising uncertainty about their use in renally impaired patients. Methods: Twelve chronic hemodialysis subjects were administered two single doses of the LMWH tinzaparin, 75 IU/kg, 2 weeks apart: subcutaneously (SC) on an off-dialysis day and intravenously (IV) just before dialysis. Results: Mean maximal anti-factor Xa (anti-Xa) activity was 0.33 IU/mL 4.0 hours after SC administration and 1.33 IU/mL 0.25 hours after IV administration. Anti-Xa half-lives were 3.89 and 2.31 hours, respectively. Anti-Xa activity returned to baseline within 24 hours of administration by either route. Consistent with population pharmacokinetic analyses of clinical study subjects with severe renal impairment, anti-Xa clearance after tinzaparin administration was reduced 28% relative to subjects with normal renal function. All 12 study subjects completed hemodialysis without requiring additional anticoagulation. One subject had minimal clotting in the dialyzer drip chamber, and one subject had mild prolonged bleeding at the vascular access site after dialysis needle removal. No major bleeding events occurred. Conclusion: Tinzaparin, 75 IU/kg, SC on an off-dialysis day and IV just before dialysis is well tolerated in chronic hemodialysis patients. The weight-based regimen of 75 IU/kg IV just before dialysis provides adequate anticoagulation. SC weight-based dosing on off-dialysis days is a feasible regimen for further clinical thromboprophylaxis efficacy studies in hemodialysis patients. The risk for clinical overdose in severely renally impaired patients using this weight-based regimen of tinzaparin is unlikely.

Original languageEnglish (US)
Pages (from-to)531-538
Number of pages8
JournalAmerican Journal of Kidney Diseases
Issue number3
StatePublished - Sep 2002
Externally publishedYes

Bibliographical note

Funding Information:
Supported in part by Bristol-Myers Squibb Pharma Company, Wilmington, DE; Research Services of Veterans Administration Puget Sound Health Care System; and Northwest Kidney Centers, Seattle, WA.


  • Anti-factor Xa (anti-Xa)
  • Anticoagulation
  • Deep-vein thrombosis (DVT)
  • End-stage renal disease (ESRD)
  • Hemodialysis (HD)
  • Innohep
  • Low molecular weight heparin (LMWH)
  • Pharmacodynamics
  • Pharmacokinetics
  • Renal failure
  • Thromboprophylaxis
  • Tinzaparin


Dive into the research topics of 'Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis'. Together they form a unique fingerprint.

Cite this